Abstract
There has been an exponential increase of warfarin usage in the community since several large and well-designed clinical trials have consistently found that warfarin can safely prevent embolic stroke in people with atrial fibrillation. Safe and effective warfarin treatment requires a case-by-case evaluation of each patient's clinical condition and risk factors for bleeding. It also demands a therapeutic partnership where patients can accept an educated responsibility for managing their own condition. This requires mutually understood plans for ongoing management, including dose adjustment and responses to under- or overdose and to bleeding complications.
| Original language | English |
|---|---|
| Pages (from-to) | 55-59 |
| Number of pages | 5 |
| Journal | Journal of Quality in Clinical Practice |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 1999 |
| Externally published | Yes |
Keywords
- Anticoagulant
- Bleeding risk
- Patient education
- Warfarin therapy
